Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.
The financing was co-led by Canaan and New Leaf Venture Partners, and included abrdn Inc., Mayo Clinic Ventures and Correlation Ventures as well.
The drug is under development to relieve IOP by reducing distal outflow resistance and episcleral venous pressure (EVP). QLS-111 is being tested for safety, tolerability, optimal dosing and efficacy in two phase 2 trials among patients (Read more...)